| 1 |
Sairenji T，Collins KL，Evans DV.An Update on Inflammatory Bowel Disease[J]．Primary Care，2017，44(4)：673-692.
|
| 2 |
Mak WY，Zhao M，Ng SC，et al.The epidemiology of inflammatory bowel disease：East meets west[J]．J Gastroenterol Hepatol，2020，35(3)：380-389.
|
| 3 |
Guan Q．A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease[J]．Journal of Immunology Research，2019，2019：1-16.
|
| 4 |
Moschen AR，Tilg H，Raine T．IL-12，IL-23 and IL-17 in IBD：immunobiology and therapeutic targeting[J]．Nat Rev Gastroenterol Hepatol，2019，16(3)：185-196.
|
| 5 |
Ahluwalia B，Moraes L，Magnusson MK，et al.Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies[J]．Scand J Gastroenterol，2018，53(4)：379-389.
|
| 6 |
Leppkes M，Neurath MF.Cytokines in inflammatory bowel diseases-Update 2020[J]．Pharmacol Res，2020，158：104835.
|
| 7 |
Flynn S，Eisenstein S．Inflammatory Bowel Disease Presentation and Diagnosis[J]．Surgical Clinics of North America，2019，99(6)：1051-1062.
|
| 8 |
Katsanos KH，Papadakis KA.Inflammatory Bowel Disease：Updates on Molecular Targets for Biologics[J]．Gut Liver，2017，11(4)：455-463.
|
| 9 |
Weisshof R，El J K，Zmeter N，et al.Emerging Therapies for Inflammatory Bowel Disease[J]．Adv Ther，2018，35(11)：1746-1762.
|
| 10 |
Cai Z，Wang S，Li J．Treatment of Inflammatory Bowel Disease：A Comprehensive Review[J]．Front Med(Lausanne)，2021，8：765474.
|
| 11 |
Feuerstein JD，Isaacs KL，Schneider Y，et al.AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis[J]．Gastroenterology，2020，158(5)：1450-1461.
|
| 12 |
Raine T，Bonovas S，Burisch J，et al.ECCO Guidelines on Therapeutics in Ulcerative Colitis：Medical Treatment[J]．J Crohns Colitis，2022，16(1)：2-17.
|
| 13 |
Fredericks E，Watermeyer G．De-escalation of biological therapy in inflammatory bowel disease：Benefits and risks[J]．S Afr Med J，2019，109(10)：745-749.
|
| 14 |
Kirchgesner J，Lemaitre M，Carrat F，et al.Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases[J]．Gastroenterology，2018，155(2)：337-346.
|
| 15 |
Hindryckx P，Novak G，Bonovas S，et al.Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease[J]．Clin Pharmacol Ther，2017，102(4)：633-641.
|
| 16 |
Prasad M，Lambe UP，Brar B，et al.Nanotherapeutics：An insight into healthcare and multi-dimensional applications in medical sector of the modern world[J]．Biomedicine & Pharmacotherapy，2018，97：1521-1537.
|
| 17 |
Sohail M，Mudassir，Minhas MU，et al.Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis：a review of recent developments and future prospects[J]．Drug Deliv Transl Res，2019，9(2)：595-614.
|
| 18 |
Jain KK.An Overview of Drug Delivery Systems[J]．Methods Mol Biol，2020，2059：1-54.
|
| 19 |
Chauhan D，Sri S，Kumar R，et al.Evaluation of size，shape，and charge effect on the biological interaction and cellular uptake of cerium oxide nanostructures[J]．Nanotechnology，2021，32(35)．
|
| 20 |
Cotin G，Blanco-Andujar C，Perton F，et al.Unveiling the role of surface，size，shape and defects of iron oxide nanoparticles for theranostic applications[J]．Nanoscale，2021，13(34)：14552-14571.
|
| 21 |
Yang J，Jia C，Yang J．Designing Nanoparticle-based Drug Delivery Systems for Precision Medicine[J]．International Journal of Medical Sciences，2021，18(13)：2943-2949.
|
| 22 |
Mitchell MJ，Billingsley MM，Haley RM，et al.Engineering precision nanoparticles for drug delivery[J]．Nat Rev Drug Discov，2021，20(2)：101-124.
|
| 23 |
Pandey V，Haider T，Chandak AR，et al.Surface modified silk fibroin nanoparticles for improved delivery of doxorubicin：Development，characterization，in-vitro studies[J]．International Journal of Biological Macromolecules，2020，164：2018-2027.
|
| 24 |
Shi Y，van der Meel R，Chen X，et al.The EPR effect and beyond：Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy[J]．Theranostics，2020，10(17)：7921-7924.
|
| 25 |
Watanabe A，Tanaka H，Sakurai Y，et al.Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium(DSS)-induced colitis model[J]．Int J Pharm，2016，509(1/2)：118-122.
|
| 26 |
Takechi-Haraya Y，Ohgita T，Demizu Y，et al.Current Status and Challenges of Analytical Methods for Evaluation of Size and Surface Modification of Nanoparticle-Based Drug Formulations[J]．AAPS Pharm Sci Tech，2022，23(5)：150.
|
| 27 |
Cui M，Zhang M，Liu K．Colon-targeted drug delivery of polysaccharide-based nanocarriers for synergistic treatment of inflammatory bowel disease：A review[J]．Carbohydrate Polymers，2021，272：118530.
|
| 28 |
Hartwig O，Shetab Boushehri MA，Shalaby KS，et al.Drug delivery to the inflamed intestinal mucosa-targeting technologies and human cell culture models for better therapies of IBD[J]．Advanced Drug Delivery Reviews，2021，175：113828.
|
| 29 |
Bannister AH，Bromma K，Sung W，et al.Modulation of nanoparticle uptake，intracellular distribution，and retention with docetaxel to enhance radiotherapy[J]．Br J Radiol，2020，93(1106)：20190742.
|
| 30 |
Grattoni A，Cooke JP.Emerging nanotechnologies in cardiovascular medicine[J]．Nanomedicine，2022，39：102472.
|
| 31 |
Stephen BJ，Suchanti S，Mishra R，et al.Cancer Nanotechnology in Medicine：A Promising Approach for Cancer Detection and Diagnosis[J]．Crit Rev Ther Drug Carrier Syst，2020，37(4)：375-405.
|
| 32 |
Garbayo E，Pascual Gil S，Rodríguez Nogales C，et al.Nanomedicine and drug delivery systems in cancer and regenerative medicine[J]．WIREs Nanomedicine and Nanobiotechnology，2020，12(5)：e1637.
|
| 33 |
Click B，Regueiro M．Managing Risks with Biologics[J]．Curr Gastroenterol Rep，2019，21(2)：1.
|
| 34 |
Nidhi，Dadwal A，Hallan SS，et al.Development of enteric-coated microspheres of embelin for their beneficial pharmacological potential in ulcerative colitis[J]．Artif Cells Nanomed Biotechnol，2017，45(6)：1-9.
|
| 35 |
Da Silva FLO，Marques MBDF，Kato KC，et al.Nanonization techniques to overcome poor water-solubility with drugs[J]．Expert Opin Drug Discov，2020，15(7)：853-864.
|
| 36 |
Wang Y，Pi C，Feng X，et al.The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs [J]．Int J Nanomedicine，2020，15：6295-6310.
|
| 37 |
Xu Y，Shrestha N，Preat V，et al.Overcoming the intestinal barrier：A look into targeting approaches for improved oral drug delivery systems[J]．J Control Release，2020，322：486-508.
|
| 38 |
Gao M，Yang C，Wu C，et al.Hydrogel-metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis[J]．J Nanobiotechnology，2022，20(1)：404.
|
| 39 |
Naeem M，Lee J，Oshi M A，et al.Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis[J]．Acta Biomaterialia，2020，116：368-382.
|
| 40 |
Chen Y，Song W，Shen L，et al.Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors[J]．ACS Nano，2019，13(2)：1751-1763.
|
| 41 |
Qiu N，Gao J，Liu Q，et al.Enzyme-Responsive Charge-Reversal Polymer-Mediated Effective Gene Therapy for Intraperitoneal Tumors[J]．Biomacromolecules，2018，19(6)：2308-2319.
|
| 42 |
Miao L，Guo S，Lin C M，et al.Nanoformulations for combination or cascade anticancer therapy[J]．Adv Drug Deliv Rev，2017，115：3-22.
|
| 43 |
杨花花，周旭春，黄怡，等．治疗炎症性肠病常见的生物制剂[J]．中国医药科学，2022，12(8)：68-71.
|
| 44 |
Jeong DY，Kim S，Son MJ，et al.Induction and maintenance treatment of inflammatory bowel disease：A comprehensive review[J]．Autoimmun Rev，2019，18(5)：439-454.
|
| 45 |
Katsanos KH，Papadakis KA.Inflammatory Bowel Disease：Updates on Molecular Targets for Biologics[J]．Gut and Liver，2017，11(4)：455-463.
|
| 46 |
Li X，Yu M，Zhu Z，et al.Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease[J]．Carbohydrate Polymers，2021，273：118556.
|
| 47 |
Fattal E，Fay F．Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases[J]．Adv Drug Deliv Rev，2021，175：113809.
|
| 48 |
Huang Y，Guo J，Gui S．Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid)nanoparticles loaded with TNF-a siRNA provide a novel strategy for the experimental treatment of ulcerative colitis[J]．Eur J Pharm Sci，2018，125：232-243.
|
| 49 |
Ma Y，Gao W，Zhang Y，et al.Biomimetic MOF Nanoparticles Delivery of C-Dot Nanozyme and CRISPR/Cas9 System for Site-Specific Treatment of Ulcerative Colitis[J]．ACS Applied Materials & Interfaces，2022，14(5)：6358-6369.
|
| 50 |
You Y，Zhou C，Li D，et al.Sorting nexin 10 acting as a novel regulator of macrophage polarization mediates inflammatory response in experimental mouse colitis[J]．Sci Rep，2016，6：20630.
|
| 51 |
Bao W，Wu Q，Hu B，et al.Oral Nanoparticles of SNX10-shRNA Plasmids Ameliorate Mouse Colitis[J]．Int J Nanomedicine，2021，16：345-357.
|
| 52 |
Sun T，Kwong C，Gao C，et al.Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine[J]．Theranostics，2020，10(22)：10106-10119.
|
| 53 |
Zhang M，Xu C，Liu D，et al.Oral Delivery of Nanoparticles Loaded With Ginger Active Compound，6-Shogaol，Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis[J]．J Crohn′s Colitis，2018，12(2)：217-229.
|
| 54 |
Fan W，Zhang S，Wu Y，et al.Genistein-Derived ROS-Responsive Nanoparticles Relieve Colitis by Regulating Mucosal Homeostasis[J]．ACS Applied Materials & Interfaces，2021，13(34)：40249-40266.
|
| 55 |
Feng Z，Jiao L，Wu Z，et al.A Novel Nanomedicine Ameliorates Acute Inflammatory Bowel Disease by Regulating Macrophages and T-Cells[J]．Molecular Pharmaceutics，2021，18(9)：3484-3495.
|
| 56 |
Diez-Echave P，Ruiz-Malagón AJ，Molina-Tijeras JA，et al.Silk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitis[J]．Int J Pharmaceutics，2021，606：120935.
|
| 57 |
Asgharzadeh F，Hashemzadeh A，Rahmani F，et al.Cerium oxide nanoparticles acts as a novel therapeutic agent for ulcerative colitis through anti-oxidative mechanism[J]．Life Sci，2021，278：119500.
|
| 58 |
Gou S，Huang Y，Wan Y，et al.Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis[J]．Biomaterials，2019，212：39-54.
|
| 59 |
Li C，Zhao Y，Cheng J，et al.A Proresolving Peptide Nanotherapy for Site-Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota[J]．Adv Sci(Weinh)，2019，6(18)：1900610.
|
| 60 |
Lee Y，Sugihara K，Gillilland MR，et al.Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier，microbiome and immune responses in colitis[J]．Nat Mater，2020，19(1)：118-126.
|
| 61 |
Yan L，Zhao F，Wang J，et al.A Safe-by-Design Strategy towards Safer Nanomaterials in Nanomedicines[J]．Advanced Materials，2019，31(45)：1805391.
|
| 62 |
Zielińska A，Costa B，Ferreira MV，et al.Nanotoxicology and Nanosafety：Safety-by-Design and Testing at a Glance[J]．Int J Environ Res Public Health，2020，17(13)：4657.
|